Company Overview
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Why Investors Should Care
Revenue has grown at a 101.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $7.70M (+0.1% YoY); net profit $-33.38M.
- Trailing 12 Months Year-on-year growth — revenue -99.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 101.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 101.61% |
| 1 Year: | -99.70% |
Stock Price Performance
| 1 Year: | -31.32% |
| 6 Months: | -6.31% |
| 3 Months: | -18.22% |
| 1 Month: | -4.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)51.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 101.6% over 5 years.
CONS
- Trading 45.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BOLT Bolt Biotherapeutics, Inc. PHARMA | 3.86 | -0.23 | $7.44M | 0.00% | -74.75% | -111.65% | 101.61% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.00K | 67.00K | - | - | 0 | 752.00K | 813.00K | 1.39M | 2.11M | 1.83M | 1.43M | 2.53M | 5.27M | 1.27M | 1.14M | 1.22M | 1.80M | 2.17M | 26.00K |
| Operating Income | -8.74M | -11.11M | -12.40M | -18.43M | -23.76M | -23.53M | -23.88M | -23.06M | -22.35M | -18.41M | -19.83M | -18.18M | -17.09M | -22.60M | -16.44M | -12.12M | -9.21M | -7.70M | -7.60M |
| Net Income | -8.63M | -11.06M | -10.00M | -24.45M | -23.59M | -23.39M | -23.68M | -22.66M | -21.76M | -16.98M | -18.06M | -16.26M | -10.81M | -21.20M | -15.18M | -11.04M | -8.56M | -7.14M | -7.24M |
| Diluted EPS | - | - | - | - | - | -0.63 | -0.64 | -0.61 | -0.58 | -0.45 | -0.48 | -0.43 | -0.28 | -11.12 | -7.93 | -5.76 | -4.46 | -3.72 | -4.31 |
| R&D Expense | 6.79M | 9.17M | 9.54M | 14.13M | 19.71M | 19.34M | 18.39M | 18.92M | 18.97M | 14.62M | 15.64M | 14.95M | 16.53M | 15.43M | 13.79M | 9.51M | 7.50M | 6.54M | 4.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 231.00K | 1.26M | 5.73M | 7.88M | 7.69M | 7.70M |
| Operating Income | -49.18M | -92.79M | -90.32M | -76.20M | -73.05M | -36.11M |
| Net Income | -60.73M | -98.59M | -88.10M | -69.20M | -63.12M | -33.38M |
| Diluted EPS | - | -2.97 | -2.36 | -1.83 | -33.06 | -17.85 |
| R&D Expense | 40.36M | 75.66M | 73.12M | 61.54M | 57.47M | 28.53M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 46.54M | 307.72M | 227.81M | 159.78M | 99.63M | 56.75M |
| Total Equity | -45.85M | -104.95M | 250.12M | 171.51M | 112.74M | 57.20M | 26.50M |
| Cash & Equivalents | - | 5.54M | 27.38M | 9.24M | 10.81M | 7.21M | 11.70M |
| Total Liabilities | - | 46.19M | 57.60M | 56.30M | 47.04M | 42.43M | 30.24M |
| Current Liabilities | - | 11.26M | 21.33M | 23.12M | 20.46M | 15.86M | 8.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -47.31M | - | -76.50M | -69.53M | -61.29M | -39.85M |
| Investing Cash Flow | -20.59M | - | 57.86M | 71.04M | 57.58M | 44.30M |
| Financing Cash Flow | 39.60M | - | 503.00K | 253.00K | 108.00K | 19.00K |
| Capital Expenditure | -3.26M | - | -1.95M | -206.00K | -41.00K | -72.00K |
| Free Cash Flow | -50.57M | - | -78.46M | -69.73M | -61.33M | -39.92M |
| Net Change in Cash | - | - | -18.14M | 1.77M | -3.60M | 4.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -21,290.9% | -7,364.1% | -1,576.6% | -967.4% | -949.9% | -469.3% |
| Net Margin % | -26,289.2% | -7,824.7% | -1,537.8% | -878.6% | -820.8% | -433.7% |
| ROE % | 57.9% | -39.4% | -51.4% | -61.4% | -110.4% | -125.9% |
| ROCE % | -139.4% | -32.4% | -44.1% | -54.7% | -87.2% | -74.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sofinnova Investments, Inc. | 7.15% | 137.72K | $490.29K |
| 2 | Renaissance Technologies, LLC | 5.12% | 98.62K | $351.10K |
| 3 | Vivo Capital, LLC | 3.76% | 72.41K | $257.79K |
| 4 | Citadel Advisors Llc | 2.95% | 56.90K | $202.57K |
| 5 | T3 Companies, LLC | 1.97% | 38.00K | $135.28K |
| 6 | Board Of Trustees Of The Leland Stanford Junior University | 1.87% | 35.98K | $128.08K |
| 7 | Pfizer Inc | 1.63% | 31.30K | $111.44K |
| 8 | Lynx1 Capital Management Lp | 1.60% | 30.80K | $109.65K |
| 9 | Nano Cap New Millennium Growth Fund L P | 1.43% | 27.50K | $97.90K |
| 10 | Geode Capital Management, LLC | 0.99% | 19.12K | $68.06K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BOLT
WOOX Elegante Bolt-Action Line and High-Grade Furniture Exceed Expectations - Outdoor Wire
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQd0FiWEtBellXaEpybTgxOW02R253dXd1OVpGT2JhMDVOOVZzZGYyaFV4NS1XNVBINmdRazQ0Y3d6YXMydkpHaGlwV0pIeE9lMzdNbHRNSWpRVlAxX1BrNTJiVGcxWlB4djZhWkQ1VnVpbUFPNWtuOVo2S1c0akt0TkFUWHlfdEx4dmRhT3…
Usain Bolt Just Got an AI Rival – Meet the Stocks Behind It - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPRVdoUHhBbGhZYzhQa09pY3ktckp6cUJYdHZ3ZGk3V1FnNWxTcURUa0JZM1pUR1ZrSjVEaDFWSTRvcWFVN015NHA2YVBJWDIxazRYS0NtaHNQdGRHcktHLVprYzdpX1hsMXdaOHprSHpsYi1LaGFYM1RSSm41ZFVoZmRCRW9lZ2FvMTdFTW…
BOLT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBnZmVtUV9Va1FRTkhqUmtyazk0WGctNG5qNmRTbVY0b0c3RllOMUNOMmd1aUpTVVBpMzltMTREQ2ZLaTVFaGc?oc=5" target="_blank">BOLT</a> <font color="#6f6f6f">Finviz</font>…
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQVGJkYm84NTFFclRPSi1WRjdOX0l1R2xBZlZ2SjBQdTI1c21NTXJvb0VINDkyZjA2cWRQYzVuQzRNNjZwQzlLMElGdjNsN1RMZXhULVFNcjRxZ0dtSk1lU2xXV3RNc191TGNSdzhFQ0JKUVlRUEdBaGk4UlVaU1lXdERaa2VnbGc5N1dPLX…
Bolt riders in Europe get Klarna checkout for daily commutes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQRnM1Tnc1WjhoWjJmNjBmUGlnc3VUbnFrMERrSHVfRmM0UXQyQXI4NEFyeE9mdjQ5U3FraWdaMkhwdkIzXzNkQ2hMenMwR1FSWGowVjcxc2ZqU0pnZTlVeFZtd2RkWXVFLUdYaWdZSGx0RDIzV2Z6V21veWk0Z0pBUHc3ZXNldVlISFc2el…
RKLB Stock Keeps Flying Overnight: Analyst Says Rocket Lab Outbid ASTS, Other Rivals For Iridium In 'Bolt From The Blue' Deal - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGVhMHJLWnc2aGE5LVkxQjFHdkwwaVdKSmZkcmhIdEdBMUgzTkdYbjRNV2c5Z3dTYjgyb0lDdWxYVmZJdUFEMXN4eUt6U2VhUEZzVUs2SWVFMnQ0eTJrSkVlY3BFdHc3ME5IaWZmbG8yTFo5ZDkxM1R0MkllSlNSRTNvWm1Wa3N1WjdwMH…
BOLT — Frequently Asked Questions
What is the current share price of Bolt Biotherapeutics, Inc. (BOLT)?
As of 2026-09-19 21:16 PDT, Bolt Biotherapeutics, Inc. (BOLT) trades at $3.86 on NasdaqCM. Its 52-week range is $3.18 to $7.09.
What is the market capitalisation of BOLT?
Bolt Biotherapeutics, Inc. (BOLT) has a market capitalisation of $7.44M on NasdaqCM.
What is the P/E ratio of BOLT?
BOLT trades at a trailing price-to-earnings (P/E) ratio of -0.23. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.56.
What is the return on equity (ROE) of BOLT?
BOLT has a return on equity (ROE) of -111.65%. Its return on capital employed (ROCE) is -74.75%.
Is BOLT a good stock to buy?
This page provides a data-driven analysis of Bolt Biotherapeutics, Inc. (BOLT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.